# ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome

> **NCT04304482** · PHASE2,PHASE3 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 92 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** ANAVEX2-73 oral liquid
- **DRUG:** Placebo oral liquid

## Key facts

- **NCT ID:** NCT04304482
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-30
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04304482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04304482, "ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04304482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*